How to improve pharmacoeconomic data generalisability between different countries

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 10, 2007, Pages 1409-1413

  Li, Shu Chuen ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Data transferability; Generalisability; ISPOR; Pharmacoeconomics

Indexed keywords

DRUG;

AUSTRALIA; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DECISION MAKING; DRUG FORMULARY; ECONOMIC EVALUATION; EDITORIAL; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INFORMATION PROCESSING; PRACTICE GUIDELINE;

COST-BENEFIT ANALYSIS; DATA COLLECTION; DECISION MAKING, ORGANIZATIONAL; DRUG COSTS; DRUG EVALUATION; ECONOMICS, PHARMACEUTICAL; FORMULARIES; GUIDELINES; HUMANS; INTERNATIONAL COOPERATION; REPRODUCIBILITY OF RESULTS;

EID: 34447539593     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.10.1409     Document Type: Editorial

References (21)

1. COMMONWEALTH DEPARTMENT OF HEALTH, HOUSING AND COMMUNITY SERVICES: Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisery Committee. Australian Government Publishing Service, Canberra (1992).
2. JOHANNESSON M: Economic evaluation of drugs and its potential uses in policy making. Pharmacoeconomics (1995) 8(3):190-198.
3. DRUMMOND M, JONSSON B, RUTTEN F: The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy (1997) 40(3):199-215.
4. ANIS AH, GAGNON Y. Using economic evaluations to make formulary coverage decisions. So much for guidelines. Pharmacoeconomics(2000) 18(1):55-62.
5. WEST R, BORDEN EK, COLLET JP, RAWSON NS, TONKS RS: 'Cost-effectiveness estimates result in flawed decision-making in listing drugs for reimbursement. Can. J. Public Health (2002) 93(6):421-425.
6. WALTER E, ZEHETMAYR S: Guidelines for health-economic evaluations in Austria. Wien. Med. Wochenschr. (2006) 156(23-24):628-632.
7. ANELL A, PERSSON U: Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur J. Health Econ. (2005) 6(3):274-279.
8. BARBIERI M, DRUMMOND M, WILLKE R, CHANCELLOR J, JOLAIN B, TOWSE A: Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value In Health (2005) 8(1):10-23.
9. DRUMMOND MF, BLOOM BS, CARRIN G et al.: Issues in the cross-national assessment of health technology. Int. J. Technol. Assess. Healthcare (1992) 8:671-682.
10. O'BRIEN B: A tale of two (or more) cities: geographic transferability of pharmacoeconomic data. Am. J Managed Care (1997) 3:S33-S39.
11. MASON J: The generalisability of pharmacoeconomic studies. Pharmacoeconomics (1997) 11:503-514.
12. DRUMMOND MF, PANG F: Transferability of economic evaluation results. In: Economic Evaluation in Healthcare: Merging Theory with Practice. Drummond MF, McGuire A (Eds), Oxford University Press, Oxford, UK (2001).
13. BOULENGER S, NIXON J, DRUMMOND MF et al.: Can economic evaluations be made more transferable? Eur. J. Health Econ. (2005) 6:334-346.
14. MASON MM, MASON AR: The generalisability of pharmacoeconomic studies issues and challenges ahead. Pharmacoeconomics (2006) 24(10):937-945.
15. DRUMMOND MF, JEFFERSON TO: Guidelines for authors and peer-reviewers of economic submissions to the Br. Med. J. The Br. Med. J. Economic Evaluation Working Party. Br. Med. J. (1996) 313:275-283.
16. HILL S, HENRY D, PEKARSKY B, MITCHELL A: Economic evaluation of pharmaceuticals: what are reasonable standards for clinical evidence - the Australian experience. Br. J. Clin. Pharmacol. (1997) 44(5):421-425.
17. WILLKE RJ, GLICK HA, POLSKY D, SCHULMAN K: Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ. (1998) 7:481-493.
18. GOLD M, SEIGEL J, RUSSELL L, WEINSTEIN MC: Cost-effectiveness in health and medicine. Oxford University Press, New York, USA (1996).
19. DRUMMOND MF, SCULPHER MJ, TORRANCE GW, O'BRIEN BJ, STODDART GL: Methods for the Economic Evaluation of Healthcare Programmes (3rd edn.). Oxford University Press, Oxford, UK (2005).
20. JACOBS P, OHINMAA A, BRADY B: Providing systematic guidance in pharmacoeconomic guidelines for analysing costs. Pharmacoeconomics (2005) 23(2):143-153.
21. DRUMMOND M, SCULPHER M: Common methodological flaws in economic evaluations. Med. Care (2005) 43(Suppl. 7):5-14.